11
Apr
2011
Posted in I - Series C, Q - 1Q11, R - INTERNATIONAL, X - Anticoagulant, X - Device (Diagnostic)
Microvisk Technologies (United Kingdom) a clinical-stage diagnostic company focused on prothrombin time assays designed to provide patients and clinicians with INR values used to aid in the correct dosage of anti-coagulation meds such as warfarin, closed a $9.5M Series C financing. Participants include Porton Capital, Oxford Technology Management, New Hill Management, Midven, Rainbow Seed Fund [...]
02
Mar
2010
03
Feb
2010
Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ
Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb